LisaACareyMD

Oncology • Chapel Hill, NC

Professor of Hematology & Oncology, University of North Carolina School of Medicine

Join to view full profile

Dr. Carey is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Carey's full profile

Already have an account?

Office
101 Manning Dr
Chapel Hill, NC 27514
Phone+1 919-966-4996

Fax+1 919-843-5515

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1993 - 1997
Johns Hopkins UniversityResidency, Internal Medicine, 1990 - 1993
Johns Hopkins University School of MedicineClass of 1990

Certifications & Licensure

NC State Medical License 1997 - 2025
MD State Medical License 1993 - 1998
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2009-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013

Clinical Trials

Multimodality Treatment for Women With Stage II, Stage III, or Stage IV Breast Cancer Start of enrollment: 1998 Dec 01
Completed
Phase 2
Cetuximab + / - Carboplatin for Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer Start of enrollment: 2005 Nov 01
Completed
Phase 2
Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen Start of enrollment: 2008 Jun 18
Completed
Phase 2
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer Start of enrollment: 2008 Oct 13
Completed
Phase 3
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery Start of enrollment: 2009 May 15
Active, not recruiting
Phase 2
Correlation of Molecular Markers With Response to Therapy and Breast Cancer Behavior Start of enrollment: 1998 Dec 01
Recruiting
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 Start of enrollment: 2012 Jan 01
Completed
Early Phase 1
Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib Start of enrollment: 2013 Aug 05
Completed
Early Phase 1
Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer Start of enrollment: 2014 Jan 30
Active, not recruiting
Phase 2
The Impact of a Physical Activity Program on Biomarkers of Aging During Chemotherapy for Breast Cancer Start of enrollment: 2014 Mar 01
Completed
The Effect of Walking on Fatigue After Chemotherapy in Patients 65 and Older Start of enrollment: 2014 Jun 01
Completed
Not Applicable
Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC Start of enrollment: 2020 Sep 23
Active, not recruiting
Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2+ early breast cancer (EBC).
Aranzazu Fernandez-Martinez, Maki Tanioka, Sung Gwe Ahn, Paola Zagami, Tomás Pascual
Annals of Oncology. 2024-12-18
Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ: The COMET Randomized Clinical Trial.
E Shelley Hwang, Terry Hyslop, Thomas Lynch, Marc D Ryser, Anna Weiss
JAMA. 2024-12-12
Immune checkpoint inhibitors for patients with metastatic triple-negative inflammatory breast cancer (INCORPORATE): An international cohort study.
Carmine Valenza, Dario Trapani, Paola Zagami, Gabriele Antonarelli, Luca Boscolo Bielo
European Journal of Cancer. 2024-12-01

Journal Articles

Integrated Analysis of RNA and DNA from a Phase III Trial of Trastuzumab-Based Neoadjuvant Chemotherapy Identifies Response Predictors in HER2-Positive Breast Cancer
Lisa Carey, MD, Clinical Cancer Research

Lectures

HER2-Targeted Therapy: Changing the Story of Breast Cancer
2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018

Authored Content

Key Immunotherapy Presentations in Early Breast Cancer from ESMO 2023: KEYNOTE-756, CheckMate-7FL, and Updated KEYNOTE-522October 2023
Endocrine-Based Therapy for Early and Metastatic Breast Cancer: New Horizons from ASCO 2023June 2023

Press Mentions

Association of Immune-Related Gene Expression Signatures and TILs with Outcomes in Early-Stage HER2-Positive Breast CancerJanuary 31st, 2023
Immune-Related Biomarkers Can Help Guide HER2+ Breast Cancer TxJanuary 24th, 2023
Study Identifies Molecular Differences Between Primary Breast Cancer and Its MetastasesJanuary 9th, 2023
Join now to see all

Grant Support

Breast Cancer ResearchNational Cancer Institute2011–2012
Academic Training In Oncology At The University Of North Carolina At Chapel HillNational Cancer Institute2011
Developmental Research ProgramNational Cancer Institute2006–2010
Lccc 0403: Phase II Cetuximab Alone And In Combination With CarboplatinNational Center For Research Resources2007
Lccc 9818: Stage IIB, Stage IIIA/B Stage IV Breast CancerNational Center For Research Resources2004–2006
Correlation Of Marker With Response To ChemotherapyNational Cancer Institute2001–2002
Tamoxifen &Raloxifene For Preventtion Of Breast CancerNational Center For Research Resources2000
Molecular Markers W/ Response To Chemotherapy In Breast CANational Center For Research Resources2000
Doxorubicin &Cyclophosphamide &Paclitaxel W/ HerceptinNational Center For Research Resources2000